Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235513 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL184776 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234621 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233979 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234757 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL17165029 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL237094 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233582 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL235645 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4106828-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | GIE Medical, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| US-20120100077-A1 | MIXTURE OF AMPHIPATHIC MOLECULES AND METHOD FOR MODIFYING CELL MEMBRANES BY MEANS OF FUSION | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2012-04-26 | — | — | US | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025061833-A1 | STEREOISOMERIC PHOSPHATIDYLOLIGOGLYCEROL | THERMOSOME GmbH (DE) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4106828-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | GIE Medical, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20120100077-A1 | MIXTURE OF AMPHIPATHIC MOLECULES AND METHOD FOR MODIFYING CELL MEMBRANES BY MEANS OF FUSION | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100077-A1 | MIXTURE OF AMPHIPATHIC MOLECULES AND METHOD FOR MODIFYING CELL MEMBRANES BY MEANS OF FUSION | ANXA2, DNM2, ANXA6 | SMN1; SMN2 3562/4885NR5A2 4747/4885NR5A1 4677/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | SMN1; SMN2 1150/4885NR5A2 2095/4885NR5A1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.